Biocad

This study tests a new drug, BCD-261, against a placebo in 204 adults with moderate to severe active Crohn's disease who have not responded well to previous treatments. The goal is to see if BCD-261 can reduce symptoms and heal the gut lining. Participants will be randomly assign…

This study tests a single dose of a gene therapy called ANB-002 in adults with hemophilia B, a bleeding disorder. The goal is to see if it can reduce the number of bleeding episodes compared to standard preventive treatment with clotting factor. About 24 men with severe hemophili…

This study tests a new medicine called BCD-281 for people with relapsing-remitting multiple sclerosis (RRMS). The goal is to see if it reduces brain lesions and relapses better than an existing drug. About 292 adults aged 18-55 with RRMS will take part. The trial is currently rec…

This study tests a new drug called BCD-261 in about 198 adults with moderate to severe ulcerative colitis who haven't responded well to standard treatments. Participants will receive either BCD-261 or a placebo to see if the drug can reduce symptoms and inflammation. The goal is …

This study is testing a new drug called BCD-057 (in two strengths) against the approved drug Humira. It involves 444 healthy men aged 18-45 who will receive a single injection. The goal is to see how the drugs move through the body, how safe they are, and whether the body reacts …